Survival Differences in High-Risk Prostate Cancer by Age

被引:0
|
作者
Garcia-Fuentes, Clara [1 ]
Guijarro, Ana [1 ]
Hernandez, Virginia [1 ]
Gonzalo-Balbas, Alvaro [1 ]
Jimenez-Alcaide, Estibaliz [1 ,3 ]
de la Pena, Enrique [1 ]
Perez-Fernandez, Elia [2 ]
Llorente, Carlos [1 ]
机构
[1] Hosp Univ Fdn Alcorcon, Dept Urol, Madrid, Spain
[2] Hosp Univ Fdn Alcorcon, Res Unit, Madrid, Spain
[3] Hosp Univ Fdn Alcorcon, Dept Urol, Avda Budapest 1, Alcorcon 28922, Madrid, Spain
关键词
high-risk prostate cancer; age groups; survival differences; LONG-TERM SURVIVAL; RADICAL PROSTATECTOMY; RADIATION-THERAPY; MEN; COMORBIDITY; RADIOTHERAPY; IMPACT; DEATH;
D O I
10.22037/uj.v20i.7393
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: Age is an established determining factor in survival in low-risk prostate cancer (PC), being this evidence weaker in high-risk tumors. Our aim is to evaluate the survival of patients with high-risk PC treated with curative intent and to identify differences across ages at diagnosis.Methods: We did a retrospective analysis of patients with high-risk PC treated with surgery (RP) or radiotherapy (RDT) excluding N+ patients. We divided patients by age groups: < 60, 60-70, and > 70 years. We performed a comparative survival analysis. A multivariate analysis adjusted for clinically relevant variables and initial treat-ment received was performed.Results: Of a total of 2383 patients, 378 met the selection criteria with a median follow-up of 8.9 years: 38 (10.1%) < 60 years, 175 (46.3%) between 60-70 years, and 165 (43.6%) >70 years. Initial treatment with surgery was predominant in the younger group (RP:63.2%, RDT:36.8%), and with radiotherapy in the older group (RP:17%, RDT:83%) (p = 0.001). In the survival analysis, significant differences were observed in overall survival, with better results for the younger group. However, these results were reversed in biochemical recurrence-free survival, with patients < 60 years presenting a higher rate of biochemical recurrence at 10 years. In the multivariate analysis, age behaved as an independent risk variable only for overall survival, with a HR of 2.8 in the group >70 years (95%CI: 1.22-6.5; p = 0.015).Conclusion: In our series, age appeared to be an independent prognostic factor for overall survival, with no differ-ences in the rest of the survival rates.
引用
收藏
页码:215 / 221
页数:7
相关论文
共 50 条
  • [31] Results of surgery for high-risk prostate cancer
    Joniau, Steven
    Tosco, Lorenzo
    Briganti, Alberto
    Vanden Broeck, Thomas
    Gontero, Paolo
    Karnes, R. Jeffrey
    Spahn, Martin
    Van Poppel, Hein
    CURRENT OPINION IN UROLOGY, 2013, 23 (04) : 342 - 348
  • [32] PET/CT in High-Risk Prostate Cancer
    不详
    JOURNAL OF NUCLEAR MEDICINE, 2012, 53 (06) : 30N - 30N
  • [33] Surgery for high-risk localized prostate cancer
    Schmitges, Jan
    Trinh, Quoc-Dien
    Walz, Jochen
    Graefen, Markus
    THERAPEUTIC ADVANCES IN UROLOGY, 2011, 3 (04) : 173 - 182
  • [34] Radical prostatectomy for high-risk prostate cancer
    Yossepowitch, Ofer
    Eastham, James A.
    WORLD JOURNAL OF UROLOGY, 2008, 26 (03) : 219 - 224
  • [35] Concurrent chemoradiation for high-risk prostate cancer
    Cooper, Benjamin T.
    Sanfilippo, Nicholas J.
    WORLD JOURNAL OF CLINICAL ONCOLOGY, 2015, 6 (04): : 35 - 42
  • [36] Management of High-Risk Localized Prostate Cancer
    Marciscano, Ariel E.
    Hardee, Matthew E.
    Sanfilippo, Nicholas
    ADVANCES IN UROLOGY, 2012, 2012
  • [37] Adjuvant Therapy in High-Risk Prostate Cancer
    Shevach, Jeffrey
    Chaudhuri, Parul
    Morgans, Alicia K.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (01) : 45 - 53
  • [38] The role of surgery for high-risk prostate cancer
    Ucer, Oktay
    Muezzinoglu, Talha
    UROONKOLOJI BULTENI-BULLETIN OF UROONCOLOGY, 2014, 13 (01): : 21 - 24
  • [39] Approach to the Patient with High-Risk Prostate Cancer
    Mossanen, Matthew
    Krasnow, Ross E.
    Nguyen, Paul L.
    Trinh, Quoc D.
    Preston, Mark
    Kibel, Adam S.
    UROLOGIC CLINICS OF NORTH AMERICA, 2017, 44 (04) : 635 - +
  • [40] Management of High-Risk Localised Prostate Cancer
    Ozen, Haluk
    Yazici, Sertac
    Inci, Kubilay
    EUROPEAN UROLOGY SUPPLEMENTS, 2009, 8 (05) : 439 - 447